Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 18/20 | 0.69 |
| ▸ | CLK3 | P49761 | 17/20 | 0.69 |
| ▸ | CLK2 | P49760 | 16/20 | 0.69 |
| ▸ | WNT1 | P04628 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13655258 | 0.87 | CLK3 (0.72) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL13655288 | 0.86 | CLK3 (0.69) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18444352 | 0.82 | CLK2 (0.74) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18447182 | 0.82 | CLK2 (0.73) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18485128 | 0.82 | CLK3 (1.00) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18446560 | 0.82 | CLK3 (0.82) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL13655287 | 0.82 | CHEK1 (0.68) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL20455128 | 0.80 | CLK3 (0.81) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18448749 | 0.80 | CLK2 (0.75) | DYRK1ACLK3CLK2WNT1 | |
| SCHEMBL18441169 | 0.80 | CLK2 (0.75) | DYRK1ACLK3CLK2WNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MERCK SHARP & DOHME LIMITED (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247504-A1 | Indazole Derivatives for Treatment of Alzheimer's Disease | MAPT, PSEN2, PSEN1 | DYRK1A 1225/4885CLK3 1342/4885CLK2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.